Sonoma Biotherapeutics rallies $265m Series B

Sonoma Biotherapeutics, a developer of regulatory T cell therapies, has secured $265 million in Series B financing.

Sonoma Biotherapeutics, a developer of regulatory T cell therapies, has secured $265 million in Series B financing. Ally Bridge Group led the round.

Source: Press Release